Irène Juhan-Vague mostly deals with Internal medicine, Endocrinology, Plasminogen activator, Plasminogen activator inhibitor-1 and Insulin resistance. Internal medicine and Surgery are commonly linked in her work. Her study brings together the fields of Activator and Endocrinology.
The Plasminogen activator study combines topics in areas such as Thrombosis, Tissue plasminogen activator and Immunology. The various areas that Irène Juhan-Vague examines in her Insulin resistance study include Low-density lipoprotein and Weight loss. The concepts of her Fibrinolysis study are interwoven with issues in Gastroenterology, Antigen and Fibrin.
Irène Juhan-Vague spends much of her time researching Internal medicine, Endocrinology, Plasminogen activator inhibitor-1, Plasminogen activator and Fibrinolysis. Her work deals with themes such as Gastroenterology and Cardiology, which intersect with Internal medicine. Irène Juhan-Vague regularly ties together related areas like Fibrinogen in her Endocrinology studies.
Much of her study explores Plasminogen activator inhibitor-1 relationship to Molecular biology. Her Plasminogen activator research includes themes of Tissue plasminogen activator and Immunology. Irène Juhan-Vague has included themes like Antigen and Fibrin in her Fibrinolysis study.
Her scientific interests lie mostly in Internal medicine, Endocrinology, Immunology, Metabolic syndrome and Myocardial infarction. Her Internal medicine research includes elements of Diabetes mellitus and Cardiology. Insulin resistance, Adipose tissue, Plasminogen activator inhibitor-1, Plasminogen activator and Insulin are the subjects of her Endocrinology studies.
Irène Juhan-Vague usually deals with Immunology and limits it to topics linked to Cell biology and Furin, Ectodomain and Transmembrane protein. Her studies in Metabolic syndrome integrate themes in fields like Single-nucleotide polymorphism, Type 2 diabetes and Haplotype. Her work carried out in the field of Myocardial infarction brings together such families of science as Genotype, Surgery, Cohort and C-reactive protein.
Irène Juhan-Vague mainly investigates Internal medicine, Endocrinology, Immunology, Platelet and Adipose tissue. Many of her studies involve connections with topics such as Cardiology and Internal medicine. Her Metabolic syndrome study in the realm of Endocrinology interacts with subjects such as Lipoprotein receptor-related protein.
Irène Juhan-Vague interconnects Endothelium, Neuroinflammation and Cell biology in the investigation of issues within Platelet. Her research in Adipose tissue intersects with topics in Plasminogen activator and Insulin resistance. Her Plasminogen activator research is multidisciplinary, incorporating elements of Obesity and Insulin receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.
J Danesh;S Lewington;S G Thompson;Lowe Gdo..
Production of plasminogen activator inhibitor 1 by human adipose tissue : Possible link between visceral fat accumulation and vascular disease
M C Alessi;F Peiretti;P Morange;M Henry.
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
I. Juhan-Vague;M. C. Alessi;P. Vague.
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.
Paul Declerck;M C Alessi;M Verstreken;E K O Kruithof.
Correlation Between Blood Fibrinolytic Activity, Plasminogen Activator Inhibitor Level, Plasma Insulin Level, and Relative Body Weight in Normal and Obese Subjects
Philippe Vague;Irène Juhan-Vague;Marie Francoise Aillaud;Christian Badier.
Metabolism-clinical and Experimental (1986)
PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events
I Juhan-Vague;M C Alessi.
Thrombosis and Haemostasis (1997)
Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
I Juhan-Vague;J Valadier;M C Alessi;M F Aillaud.
Thrombosis and Haemostasis (1987)
C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease The PRIME Study
Gérald Luc;Jean-Marie Bard;Irène Juhan-Vague;Jean Ferrieres.
Arteriosclerosis, Thrombosis, and Vascular Biology (2003)
PAI-1 and the Metabolic Syndrome. Links, Causes, and Consequences
Marie-Christine Alessi;Irène Juhan-Vague.
Arteriosclerosis, Thrombosis, and Vascular Biology (2006)
Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.
Marie-Christine Alessi;Delphine Bastelica;Pierre Morange;Bruno Berthet.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: